Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 92.82% is in line with its 5-year average of 91.78%, around the middle of its 5-year range (88.50%–95.13%).
0.34% above its 12-month average of 92.50%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 92.95%.
GROSS MARGIN
92.82%
GROSS MARGIN AVG TTM
92.50%
GROSS MARGIN AVG 3Y
92.77%
GROSS MARGIN AVG 5Y
91.78%
GROSS MARGIN AVG 10Y
90.48%
GROSS MARGIN AVG 15Y
92.27%
GROSS MARGIN AVG 20Y
91.56%
CURRENT VS TTM AVG
+0.34%
CURRENT VS 3Y AVG
+0.05%
CURRENT VS 5Y AVG
+1.13%
CURRENT VS 10Y AVG
+2.59%
CURRENT VS 15Y AVG
+0.60%
CURRENT VS 20Y AVG
+1.38%
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+124.31%
vs the sector median at left
Vanda Pharmaceuticals Inc.
Market Cap
$271.81M
Gross Margin
92.82%
TTM Avg
92.50%
3Y Avg
92.77%
5Y Avg
91.78%
Market Cap
$270.80M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$266.92M
Gross Margin
-94.12%
TTM Avg
-431.85%
3Y Avg
-231.35%
5Y Avg
-189.25%
Market Cap
$266.59M
Gross Margin
0.00%
TTM Avg
-131.21%
3Y Avg
-60.86%
5Y Avg
-7.69%
Market Cap
$265.78M
Gross Margin
93.41%
TTM Avg
92.41%
3Y Avg
88.66%
5Y Avg
85.93%
Market Cap
$280.37M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$262.92M
Gross Margin
85.79%
TTM Avg
85.31%
3Y Avg
84.59%
5Y Avg
70.69%
Market Cap
$281.54M
Gross Margin
0.00%
TTM Avg
10.38%
3Y Avg
-887.42%
5Y Avg
-730.43%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | $271.81M | 92.82% | 92.50% | 92.77% | 91.78% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | -94.12% | -431.85% | -231.35% | -189.25% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | 0.00% | -131.21% | -60.86% | -7.69% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | 93.41% | 92.41% | 88.66% | 85.93% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 85.79% | 85.31% | 84.59% | 70.69% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | 0.00% | 10.38% | -887.42% | -730.43% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | 0.00% | -1258.31% | -887.92% |
Gross Margin
92.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 92.95% |
| 2026-03-31 | 90.05% |
| 2025-12-31 | 93.30% |
| 2025-09-30 | 94.75% |
| 2025-06-30 | 91.47% |
| 2025-03-31 | 92.96% |
| 2024-12-31 | 95.13% |
| 2024-09-30 | 94.65% |
| 2024-06-30 | 91.11% |
| 2024-03-31 | 88.50% |
| 2023-12-31 | 92.36% |
| 2023-09-30 | 92.11% |
| 2023-06-30 | 92.40% |
| 2023-03-31 | 92.36% |
| 2022-12-31 | 90.33% |
| 2022-09-30 | 90.32% |
| 2022-06-30 | 90.59% |
| 2022-03-31 | 90.59% |
| 2021-12-31 | 90.83% |
| 2021-09-30 | 90.30% |
| 2021-06-30 | 90.33% |
| 2021-03-31 | 90.38% |
| 2020-12-31 | 90.52% |
| 2020-09-30 | 90.22% |
| 2020-06-30 | 90.60% |
| 2020-03-31 | 91.02% |
| 2019-12-31 | 89.78% |
| 2019-09-30 | 88.60% |
| 2019-06-30 | 89.22% |
| 2019-03-31 | 89.28% |
| 2018-12-31 | 89.32% |
| 2018-09-30 | 89.69% |
| 2018-06-30 | 88.99% |
| 2018-03-31 | 89.54% |
| 2017-12-31 | 89.18% |
| 2017-09-30 | 89.05% |
| 2017-06-30 | 89.23% |
| 2017-03-31 | 89.30% |
| 2016-12-31 | 86.21% |
| 2016-09-30 | 81.84% |
| 2016-06-30 | 81.98% |
| 2016-03-31 | 82.09% |
| 2015-12-31 | 80.62% |
| 2015-09-30 | 77.03% |
| 2015-06-30 | 79.10% |
| 2015-03-31 | 77.36% |
| 2014-12-31 | 95.56% |
| 2014-09-30 | 95.24% |
| 2014-06-30 | 98.18% |
| 2014-03-31 | 100.00% |
| 2013-12-31 | 100.00% |
| 2013-09-30 | 100.00% |
| 2013-06-30 | 100.00% |
| 2013-03-31 | 100.00% |
| 2012-12-31 | 98.37% |
| 2012-09-30 | 100.00% |
| 2012-06-30 | 100.00% |
| 2012-03-31 | 100.00% |
| 2011-12-31 | 100.00% |
| 2011-09-30 | 100.00% |
| 2011-06-30 | 100.00% |
| 2011-03-31 | 100.00% |
| 2010-12-31 | 114.42% |
| 2010-09-30 | 94.80% |
| 2010-06-30 | 77.22% |
| 2010-03-31 | 85.96% |
| 2009-12-31 | 49.61% |
| 2009-09-30 | 0.00% |
| 2009-06-30 | 0.00% |
| 2009-03-31 | 0.00% |
| 2008-12-31 | 0.00% |
| 2008-09-30 | 0.00% |
| 2008-06-30 | 0.00% |
| 2008-03-31 | 100.00% |
| 2007-12-31 | 0.00% |
| 2007-09-30 | 0.00% |
| 2007-06-30 | 0.00% |
| 2007-03-31 | 0.00% |
| 2006-12-31 | 0.00% |
| 2006-09-30 | 0.00% |
| 2006-06-30 | 0.00% |
| 2006-03-31 | 0.00% |
| 2005-12-31 | 0.00% |
| 2005-09-30 | 0.00% |
| 2005-06-30 | 0.00% |
| 2005-03-31 | 0.00% |
